Suman Kambhampati, MD
Hematology & Oncology · Kansas City, MONPI 1437259215
Payments from drug & device makers
Across 1,107 payments — averaging $4457.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$1.1M
- Bristol Myers Squibb$692K
- Pfizer$633K
- Beigene, Ltd.$453K
- Janssen Research & Development, LLC$277K
- E.r. Squibb & Sons, L.L.C.$258K
- plus $1.5M from 30 others
Across 18 payments — averaging $4618.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$73K
- Takeda Pharmaceuticals U.S.A., Inc.$7K
- Pfizer$3K
- Pharmacyclics LLC, An Abbvie Company$434
What the payments were for
- Consulting fees$24,48480%
- Speaking & faculty fees$4,18914%
- Travel & lodging$7963%
- Food & beverage$1,2674%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 205 | $1,129,065 |
| Bristol Myers Squibb | 28 | $691,827 |
| Pfizer | 53 | $633,268 |
| Beigene, Ltd. | 167 | $453,457 |
| Janssen Research & Development, LLC | 88 | $277,132 |
| E.r. Squibb & Sons, L.L.C. | 10 | $258,195 |
| AbbVie | 72 | $232,532 |
| Incyte Corporation | 199 | $216,022 |
| Seagen Inc. | 22 | $183,319 |
| TG Therapeutics, Inc. | 99 | $133,518 |
| Morphosys AG | 13 | $127,611 |
| Eli Lilly | 10 | $125,974 |
| Astrazeneca UK Limited | 16 | $80,780 |
| Amgen | 2 | $59,608 |
| Pharmacyclics LLC, An Abbvie Company | 31 | $54,786 |
| Sanofi US Services Inc. | 8 | $52,005 |
| Karyopharm Therapeutics Inc. | 10 | $50,035 |
| AstraZeneca | 6 | $35,427 |
| Genentech, Inc. | 14 | $30,426 |
| Gilead(2 entities) | 6 | $24,585 |
| GSK | 10 | $20,049 |
| Verastem, Inc. | 11 | $18,579 |
| Acerta Pharma LLC | 4 | $18,106 |
| Taiho Oncology, Inc. | 1 | $15,000 |
| Exelixis Inc. | 2 | $9,252 |
| Beigene USA, Inc. | 1 | $2,500 |
| Foundation Medicine, Inc. | 1 | $202 |
| ADC Therapeutics America, Inc. | 1 | $131 |
| Stemline Therapeutics Inc. | 1 | $123 |
| Sanofi | 2 | $118 |
| Johnson & Johnson | 4 | $85 |
| Akcea Therapeutics, Inc. | 1 | $80 |
| Astellas Pharma US Inc | 3 | $69 |
| Secura Bio, Inc. | 3 | $58 |
| Acrotech Biopharma Inc. | 2 | $26 |
| Novartis | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NINLARO$16,138
- Blincyto$3,894
- Tecartus$1,700
- Yescarta$1,350
- FOUNDATIONONE$202
- FOUNDATIONONE HEME$202
- FOUNDATIONONE CDX$202
- FOUNDATIONFOCUS$202
- FOUNDATIONONE LIQUID CDX$202
- ZYNLONTA$131
- ELZONRIS$123
How this compares
$4,933,971 in reported general payments places this provider in the 95th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 47 | $743,651 |
| PomalystPomalidomide | 24 | $648,290 |
| ImbruvicaIbrutinib | 22 | $387,700 |
| Lenalidomide | 17 | $247,780 |
| TasignaNilotinib Hcl | 11 | $222,237 |
| BrukinsaZanubrutinib | 12 | $181,834 |
| VenclextaVenetoclax | 13 | $74,426 |
| Acyclovir | 68 | $1,202 |
| Potassium Chloride | 13 | $687 |
| Gabapentin | 31 | $484 |
| Hydroxyurea | 15 | $94 |
| Furosemide | 12 | $78 |
| Levofloxacin | 12 | $76 |
| Escitalopram Oxalate | 12 | $63 |
| Allopurinol | 18 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $691,827 | $743,65147 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $258,195 | $648,29024 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $54,786 | $387,70022 claims |
| NovartisTasigna | $20 | $222,23711 claims |
| Beigene USA, Inc.Brukinsa | $2,500 | $181,83412 claims |
| AbbVieVenclexta | $232,532 | $74,42613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Kansas City
- Stephanie GraffKansas City$6.2M
- Jaswinder SinghKansas City$3.9M
- Shahzad RazaKansas City$1.7M
- Tolga TuncerKansas City$1M
- Whitney HensingKansas City$412K
- Marc RothKansas City$257K
- Furha CossorKansas City$202K
- Frank SlovickKansas City$61K
- Lara KujtanKansas City$28K
- Geoffrey UySaint Louis$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.